CytomX Therapeutics Stock News
$1.67
+0 (+0%)
At Close: Apr 22, 2024
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
10:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
09:15pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 -
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
09:15pm, Tuesday, 01'st Mar 2022 GlobeNewswire
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 -
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
10:15pm, Monday, 28'th Feb 2022 Zacks Investment Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc
CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
01:00pm, Monday, 28'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42 nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET.
CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
08:00am, Monday, 28'th Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that S
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
01:00pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
08:00am, Tuesday, 22'nd Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it
CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer
02:00pm, Monday, 07'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the p
Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates
01:15pm, Wednesday, 26'th Jan 2022 Zacks Investment Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -15.25% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
03:41pm, Thursday, 20'th Jan 2022 Zacks Investment Research
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
12:16pm, Thursday, 20'th Jan 2022
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
CytomX rises 7% on FDA nod for phase 1 trial of CX-904 to treat solid tumors
06:15pm, Wednesday, 19'th Jan 2022 Seeking Alpha
CytomX Therapeutics <> said the the U.S. Food and Drug Administration cleared its investigational new drug application for CX-904 to enter a phase 1 trial to treating
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
01:00pm, Wednesday, 19'th Jan 2022 GlobeNewswire Inc.
- CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic - - CX-904 is CytomX’s first T-cell-engaging bispecific antibody an
